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Abstract 
INTRODUCTION: Although strict selection criteria are used to select patients for cardiac resynchronisation 
therapy, up to 30% of patients do not have a positive clinical response. 
PATIENTS: A total of 102 consecutive patients who had biventricular pacemaker/defibrillator (CRT-P or CRT-D) 
implanted were enrolled in this prospective observational study. 
RESULTS: During the average follow-up period of 24.3 months 5 patients died and 17 (16.7%) patients were 
hospitalised with the symptoms of heart failure; 75 (73.5%) patients were responders based on the previously 
defined criteria. Responders in the group of LBBB patients kept the significant difference in a computed variable 
(S1 + R6) - (S6 + R1) and R6/S6 ratio. Responders in non-LBBB patients kept the significant difference only in the 
height of R waves in V6. The R6/S6 ratio tended to be higher, but it did not reach a statistical significance. 
CONCLUSION: None of the tested ECG parameters stands out as an independent predictor of response to 
cardiac resynchronisation therapy, but some of them were different in responder-compared to the non-responder 
group. The amplitude of R wave in V6, higher R/S ratio in V6 and higher computed variable (S1 + R6) - (S6 + R1) 
may predict the likelihood of response to CRT therapy in both LBBB-patients and non-LBBB patients. 
 
 
 
 
Introduction 
 
Cardiac resynchronization therapy (CRT), 
according to ESC Guidelines for diagnoses and 
treatment of acute and chronic heart failure (HF) is 
recommended for symptomatic patients in sinus 
rhythm, LBBB-QRS morphology and left ventricular 
ejection fraction (LVEF) ≤ 35%, despite optimal 
medical treatment, in order to improve symptoms and 
reduce morbidity and mortality [1][2]. If the QRS 
duration is ≥150 ms, it is class 1 indication for CRT 
implantation, LOE A, or if the QRS duration is 130-149 
ms it is class 1 indication, LOE B. CRT should be 
considered for symptomatic patients with HF in sinus 
rhythm with a QRS duration ≥150 ms and non-LBBB 
QRS morphology and may be considered for 
symptomatic patients with HF in sinus rhythm with a 
QRS duration of 130-149 ms and non-LBBB QRS 
morphology [1]. For HF patients with atrial fibrillation 
(AF), the cut-off point for QRS duration is ≥ 130 ms 
(class IIa, LOE B) [1]. According to the same 
Guidelines CRT is contra-indicated in patients with a 
QRS duration < 130 ms, compared to 2013 guidelines 
on cardiac pacing and cardiac resynchronisation 
therapy where the cut-off point for QRS duration was 
120 ms [3].  
Despite very strong selection criteria and 
recommendation, up to 30% of patients after CRT 
implantation do not have a positive clinical response 
[4]. Responders are defined as patients who do better 
with the treatment rather than without it, regarding 
symptoms, physical activity, less frequent 
hospitalisations for HF etc. However, there is a poor 
correlation between clinical improvement and 
prognosis in heart failure patients. Variable response 
may be also due to differences in the underlying heart 
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disease. In the literature, there are few definitions of 
“responders”. Patients with NYHA-functional class III 
or IV could experience symptoms reduction, whereas 
the REVERSE trial showed no symptoms 
improvement in patients with functional class I or II 
compared to optimal drug therapy [5]. If we choose 
mortality as an endpoint or ventricular remodelling, or 
hospitalisation rate we will get a completely different 
picture of responders. Daubert C. et al. [6], in their 
practical guide to CRT, have proposed a definition of 
positive response as being alive with a sustained 
improvement in well-being, which for patients with 
moderate or severe HF means fewer hospitalisations 
and for patients with less advanced HF means no sign 
of disease progression. They have also suggested 
that remodelling of the left ventricle should be 
included in the global composite score, especially in 
patients with mild HF [6].  
As predictors of non-response, several clinical 
and echocardiographic variables have emerged from 
previous studies. Ischemic aetiology, male gender, 
NYHA functional Class IV, severe mitral regurgitation, 
left atrial dilatation, and a short interventricular 
mechanical delay has been associated with worse 
clinical or echocardiographic outcomes [7][8].  
Guidelines indicate that the QRS morphology 
is an important predictor of the therapeutic response 
to cardiac resynchronisation, giving a higher class to 
the patients with LBBB morphology in comparison to 
non -LBBB morphology patients. However, 
conventional criteria for diagnosing LBBB, including 
QRS duration > 120 msec, QS or rS in lead V1, and 
broad R waves, without Q waves in the lead I or V6 in 
the resynchronisation era seemed insufficient. ACC / 
AHA / HRS added notched, or slurred R wave in the 
lead I, aVL, V5 and V6, and occasional RS pattern in 
V5 and V6 attributed to the displaced transition of 
QRS complex [9]. It seems that prolonged duration of 
the QRS complex serves only as an indicator of the 
severity of the conduction disturbance [3]. 
Our study aimed to define more ECG criteria 
which can predict response to cardiac 
resynchronisation.  
 
 
Patients and Methods 
 
A total of 102 consecutive patients who had 
biventricular pacemaker/defibrillator (CRT-P or CRT-
D) implanted at the University Clinic of Cardiology in 
Skopje, were enrolled in this prospective 
observational study. The indications for CRT were 
according to ESC Guidelines 2013 [3]: heart failure 
symptoms despite optimal medication; New York 
Heart Association (NYHA) functional class II-IV; LVEF 
≤ 35%; and QRS duration ≥ 120 ms. Patients were 
followed for a mean of 24.3 months.  
Surface 12-lead ECGs were acquired at a 
paper speed of 25 mm/s and a scale of 10 mm / mV at 
baseline and immediately after CRT device 
implantation. All ECGs were individually reviewed by 
two investigators. To assess the reproducibility as well 
as the reliability of the ECG measurements, we 
calculated the intra-and interclass correlation 
coefficient (ICC) by assessing 20 randomly selected 
images seen in two different occasions by the same or 
two investigators. The ICC for intra-observer variability 
was in the range 0.959 – 0.983 and for inter-observer 
variability was in the range 0.974 – 0.987. QRS 
duration was measured from its first deflection to its 
end. Left bundle branch block (LBBB) was defined as 
QRS duration > 120 msec, QS or rS form in V1 and 
broad R waves, without Q waves in the lead I or V6. 
Right bundle branch block (RBBB) was defined as 
QRS duration > 120msec, with qR or rSR form in V1 
and deep S waves in the lead I and V6. Every other 
wide QRS without typical LBBB or RBBB morphology 
was classified as undetermined bundle branch (BB) 
morphology. From pre-implantation ECG we also 
analysed: R amplitude in V1 and V6, S amplitude in 
V1 and V6 and R6/S6 ratio and (S1 + R6) - (S6 + R1). 
All patients underwent complete 
echocardiography examination at baseline, at 3-6 
months and 12 months after CRT device implantation. 
Complete M-mode, 2-D, and Doppler evaluations 
were performed. Images were obtained in the 
parasternal and apical views. LV end-systolic volume, 
LV end-diastolic volume, and LVEF were calculated 
using the biplane Simpson’s technique.  
CRT device implantation was performed by 
the standard transvenous procedure. The left 
ventricular (LV) lead was advanced to a lateral vein 
or, when it was unattainable, to a postero-lateral vein. 
The right ventricular (RV) lead was implanted in the 
apex of the right ventricle. In patients with the 
indication of ICD – implantation CRT-D device was 
implanted. The right atrial lead was implanted in the 
right auricular. All devices were programmed at a 
standard atrioventricular delay after implantation with 
optimisation using echocardiography usually 
performed 3-6 months after implantation. Medications 
were recorded immediately before implantation of the 
CRT device with titration of medications made at the 
discretion of the responsible cardiologist.  
  
Definition of CRT Responder 
Patients and implanted devices were followed 
up in the outpatient clinic at 1 month after implantation 
and then at 3-6 months. To define if the patient is 
responder at 6 months follow-up we used as the 
following parameters: increase in left ventricular 
ejection fraction (LVEF) more than 10%, lowering of 
NYHA class and on the other site hospitalisation for 
heart failure in 6 months after implantation. As non – 
responders were defined all patient who were not 
alive at 6 months follow-up and patients who have 
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hospitalisation for heart failure in this period and 
responders were all patients free of hospitalisation 
either with lowering of NYHA class or increase in 
LVEF more than 10% 
  
Statistical analysis 
Categorical parameters were summarised as 
percentages and continuous parameters as mean ± 
SD. Comparisons between the two groups were 
performed using the Student’s t-test for continuous 
parameters and Pearson’s chi-square test for 
categorical parameters. Assessment of correlation 
was done using Spearman’s correlation analysis. 
Multiple logistic regression analysis was performed in 
stepwise order to determine independent predictors of 
OAC use.  
All data analysis was performed using SPSS 
version 22.0 (IBM SPSS, Inc., Chicago, Illinois) and a 
p-value ≤ 0.05 was considered significant. 
 
 
Results 
 
Patients included in this study were with a 
mean age of 62.1  9.6 years, predominantly male 
(57. 8%). Ischemic heart disease was the underlying 
aetiology of heart failure in 21.6% of patients and non-
ischemic heart disease in 78.4% of patients. Before 
implantation 41.2% of patients were in NYHA 
functional class II, 48% in class III and 10.8% were in 
class IV. Baseline rhythm was sinus in 88.2% of 
patients, 8.8% were in permanent atrial fibrillation, and 
2.9% had AV block of second or third degree. Mean 
duration of QRS complex was 171.9  22.4 ms; 74.5% 
of patients had LBBB morphology, and in other/the 
remaining 25.5% non-typical BB morphology. None of 
the patients had RBBB morphology of QRS complex.  
Implantation of the CRT device was 
successfully performed in all patients. A CRT-P device 
was implanted in 81.4% of patients, and CRT -D 
device in 18.6% of patients (74% of whom had 
ischemic aetiology of heart failure, P < 005).  
During the average follow-up period of 24.3 
months, from a total of 102 patients, 5 patients died, 
and 17 (16.7%) patients were hospitalised with 
symptoms of heart failure. Among 102 patients, 75 
(73.5%) patients were responders based on the 
previously defined criteria.  
The clinical characteristics of the responders 
and non-responders are summarised in Table 1.  
There were no significant differences in age, 
sex, the aetiology of heart failure and presence of 
arterial hypertension. Responders were more likely to 
have lower BMI, lower NYHA class, less present atrial 
fibrillation and diabetes mellitus and lower 
hospitalisation rate before CRT implantation 
compared to non-responders.  
Table 1: Clinical characteristics of patients 
 Responders (n = 75) Non-responders (n = 27) p-value 
Age 61.5  9.7 63.5   9.2 n.s. 
Gender (male %) 58.7% 55.6% n.s. 
BMI 24.9  2.4 26.2  2.1 0.012 
Etiology of HF 
(ischemic /non-ischemic) 
20% / 80% 26%/74% n.s. 
Atrial fibrillation 13.3% 33.3% 0.022 
NYHA functional class 2.6  0.6 3  0.8 0.004 
Arterial hypertension 48% 44.4%  
Diabetes mellitus 21.3% 48.1% 0.008 
Hospitalization for HF prior 
to implantation 
42.7% 70% 0.013 
BMI - Body Mass Index; HF – Heart Failure; NYHA - New York Heart Association 
 
Differences in ECG variables are listed in 
Table 2. There was no significant difference in QRS 
duration, the presence of LBBB or non-LBBB 
morphology of the QRS complex. Responders were 
more likely to have taller R waves and shorter S 
waves in V6, and bigger R6 / S6 ratio, compared to 
non-responders. The computed variable (S1 + R6) -
(S6 + R1) was also significantly bigger in responders. 
Paced QRS duration was shorter in responders than 
in non-responders, but it did not reach a statistical 
significance.  
Table 2: Electrocardiographic variables in responder and non -
responder group 
 Responders (n = 75) Non-responders (n = 27) p-value 
PR interval 162.2  23.0 182.2  32.3 0.02 
QRS duration 172.4  21.9 170.7  24.2 n.s. 
LBBB morphology 77.3% 66.7% n.s. 
R amplitude in V1 1.1  0.4 1.3  0.5 0.04 
S amplitude in V1 14.2  5.9 14.5  6.8 n.s. 
R amplitude in V6 6.6  5.0 3.6  2.9 0.01 
S amplitude in V6 4.1  3.9 7.3  6.6 0.01 
R6/S6 4.6  5.4 1.7  2.5 0.02 
(S1+R6)-(S6+R1) 15.7  10.8 9.5  8.8 0.02 
Paced QRS duration 127.5  26.3 137.0  23.2 0.08 
 
To find out if there is a difference in ECG 
parameters we divided the patient group in those with 
LBBB and those with non-LBBB morphology of the 
QRS complex. The ECG parameters of the 
responders and non-responders are summarised in 
Table 3. 
Table 3: Electrocardiographic variables in different QRS 
morphology patients 
 LBBB -patients Non LBBB -patients 
 Responders 
Non-
responders 
p-value Responders  
Non-
responders  
p-
value 
PR interval 163.624.2 180.736.1 n.s. 157.518.0 18525.63 0.02 
QRS duration 176.221.2 173.318.8 n.s. 159.519.8 165.633.2 n.s. 
R amplitude in V1 1.10.4 1.40.5 n.s. 1.10.3 1.20.4 n.s. 
S amplitude in V1 15.06.0 16.07.3 n.s. 12.15.1 11.23.7 n.s. 
R amplitude in V6 7.75.2 4.73.0 0.01 3.32.5 1.30.8 0.01 
S amplitude in V6 2.83.2 6.77.5 n.s. 7.63.7 8.54.5 n.s. 
R6/S6 5.95.6 2.42.8 0.04 0.721.2 0.170.1 0.07 
(S1+R6)-(S6+R1) 18.810.1 12.68.3 0.03 6.67.2 2.86.1 n.s. 
Paced QRS 
duration 
128.825.4 136.120.9 n.s. 122.929.7 138.928.5 n.s. 
 
Responders in the group of LBBB patients 
kept the significant difference in a computed variable 
(S1 + R6) - (S6 + R1) and R6 / S6 ratio, probably due 
to a significant difference in height in R waves in V6.  
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On the other hand, responders in the group of 
non-LBBB patients kept the significant difference only 
in the height of R waves in V6. R6 / S6 ratio in this 
group of patients tended to be higher, similar to the 
LBBB patients, but it did not reach a statistical 
significance.  
In both groups of patients, PR interval was 
longer in non-responders, but it reached statistical 
significance in non-LBBB group of patients.  
Multivariate logistic regression analysis 
identified that none of the tested ECG parameters at 
baseline is an independent predictor of response to 
cardiac resynchronisation therapy. 
Representative ECG of responders and non-
responders with LBBB and non-LBBB morphology 
before implantation are shown in Figure 1. 
 
Figure 1: Representative electrocardiograms in responder and non-responder 
group 
 
 
Discussion 
 
The baseline QRS duration is a key part of 
the indication for cardiac resynchronisation therapy. It 
has been recognised since the publication of the 
Pacing Therapies in Congestive Heart Failure (PATH -
CHF) I and II studies [10][11]. After publication of 
MADIT-CRT study in June 2009, FDA requested an 
additional 6 months of follow-up to see if the benefit of 
CRT-D persisted over time.  
It was subsequently discovered and validated 
that the LBBB subgroup patients (approximately 70% 
of the total MADIT-CRT population) received 
substantial benefit from CRT-D. Non-LBBB patients 
did not show evidence of benefit [12]. During a sub-
analysis, it was noticed that women more likely than 
men have LBBB [12]. Also, Sweeney et al. [13] have 
demonstrated that an LBBB-pattern of QRS is a 
strong predictor of response to CRT. This was further 
confirmed in the RAFT study [14]. LBBB configuration 
of the ECG was accepted as a better predictor of CRT 
response than any of the echocardiographic 
parameters [15].  
However, across the studies, approximately 
30% of the implanted CRT patients have non-LBBB 
QRS morphology: 13% have RBBB morphology and 
17% IVCD [16]. The MADIT – CRT study has shown 
that CRT implantation has led to more frequent heart 
failure events and death in patients with 
intraventricular conduction delay who received CRT -
Defibrillators compared to implantable defibrillator 
alone [8]. As cardiac resynchronisation therapy is 
largely included in the management of patients with 
heart failure a need for a new definition of LBBB 
emerged, especially to distinguish LBBB from 
conduction delay due to left ventricular hypertrophy 
(LVH). New criteria for complete LBBB have been 
proposed, which include a terminal negative deflection 
in V1, QRS duration ≥ 140 ms for men and ≥ 130 ms 
for women (due to the size of the heart in different 
genders), and also mid-QRS notching or slurring in at 
least 2 of the leads I, aVL, V1, V2, V5 or V6 [17]. The 
presence of notching is very important in establishing 
the diagnosis of LBBB, and it should begin after the 
first 40 ms of the QRS, but before 50% of QRS 
duration, when the activation wave-front reaches the 
endocardium of the LV [17]. But, if the duration of 
QRS is long enough even in non-LBBB patients, the 
number of responders to CRT increases [18].  
In our study 73.5% of patients were 
responders, and the rest of them were classified as 
non -responders. In the responder group, 22.7% of 
patients had non-LBBB morphology of the QRS, and 
opposite of that 66.7% of patients in the non -
responder group had LBBB morphology of the QRS 
complex. Some of the studies suggest that patients 
with IVCD did not respond to CRT therapy [18][19]. 
The study of Takaya et al. (20) showed that 40% of 
patients with IVCD responded to CRT. This response 
rate was lower compared to large major trials, and the 
study concluded that patients with IVCD derive fewer 
benefits from CRT therapy regarding symptoms relief 
and echocardiographic findings [21][22].  
 
ECG predictors in patients with LBBB and 
non-LBBB patterns 
Mean QRS duration in our patient group was 
171.9  22.4 ms and we found no significant 
difference between non-responders and responders, 
or between LBBB and non-LBBB pattern of QRS. In 
both ECG patterns, paced QRS was wider in non -
responder group compared to responder group, but 
this difference was not statistically significant. There is 
evidence in the literature that shortening of the QRS 
after CRT implantation is a predictor of response to 
CRT, even better than baseline QRS duration [23][24]. 
Lecoq et al. [24] reported that the only independent 
predictor of the CRT response is shortening of the 
QRS after CRT implantation. We found no statistical 
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significance of this parameter, but the results were in 
the same direction, confirming that changes in QRS 
duration after implantation may reflect the quality of 
electrical resynchronisation and the degree of 
correction of electromechanical abnormalities. 
The pattern of ventricular activation sequence 
on ECG has been very rarely analysed as a predictor. 
In our study responders in LBBB-group showed a 
significant difference in amplitude of the R wave in V6, 
computed variable (S1 + R6) - (S6 + R1) and R6 / S6 
ratio. This finding is in concordance with the Strauss 
et al. [17] explanation of the real LBBB in comparison 
to EKG changes in case of left ventricular 
hypertrophy. Absolute and relative R wave amplitude 
in V6 could serve as a simple predictor of response to 
resynchronisation therapy in patients with LBBB 
morphology.  
Responders in non-LBBB patients kept the 
significant difference only in the height of R waves in 
V6. R6 / S6 ratio in this group was higher, similar to 
LBBB patients, but it did not reach a statistical 
significance. Sweeney et al. [13] found that 
characterisation of ventricular activation sequence on 
the ECG anticipated the probability of response to 
CRT in patients with LBBB. They showed that QRS 
axis shifted from left to right, marked an increase in R-
wave amplitudes in V1 through V2 on the ECG after 
device implantation, and predicted LV reverse 
remodelling. 
Patients with non-LBBB pattern have delayed 
activation of either some or all of the right, left, or both 
ventricles. These patients may have less left-sided 
conduction delay than LBBB patients and therefore 
may not respond to CRT implantation. In the study of 
Takaya et al. [20], left axis deviation of QRS before 
implantation and QRS axis shift from left to right after 
implantation were found as predictors to CRT 
response.  
Our study has clinical importance because it 
is one step forward in identifying patients who will 
respond to CRT therapy in a very simple way like an 
electrocardiographic recording. 
Study limitations: This study is single centre 
experience, which is a limitation regarding treatment 
bias and could influence the outcome of the therapy.  
The study is prospective, but with limited 
strength, because it is observational and has no 
control group. A small number of patients studied 
arises a need for confirmation in large prospective 
studies. 
In conclusion, implantation of CRT device is a 
demandable procedure regarding sources, expertise 
and knowledge. The other part of the complexity is 
related to the disease itself, as heart failure is different 
and unpredictable in every single patient. Over the 
last decade, a majority of clinical studies have been 
focused on how to improve the selection of patients 
who will respond to this therapy-modality.  
Our study gives a contribution to the proper 
patient selection by additional electrocardiographic 
criteria. Although none of the tested ECG parameters 
stands out as an independent predictor of response to 
cardiac resynchronisation therapy, some of them were 
clearly different in responder-group compared to the 
non-responder group. The amplitude of R wave in V6, 
higher R / S ratio in V6 and higher computed variable 
(S1+R6) - (S6+R1) may predict the likelihood of 
response to CRT therapy in both, LBBB-patients and 
non-LBBB patients. 
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